Ronald Zenk is Chief Executive Officer of Minneapolis-based Humanetics Corporation. Humanetics’ product portfolio features multiple drug candidates at various stages of clinical development. Areas of focus include a therapy aimed at improving treatment for solid tumor cancers; and a therapy to prevent and treat age-related cognitive decline associated with normal aging or neurodegenerative disease (e.g. Alzheimer’s disease). Both therapies have the potential to become widely adopted new treatment paradigms that could significantly improve upon the current standard of care.

Prior to founding Humanetics, Mr. Zenk developed his business expertise as a new enterprise consultant for KPMG.  He then gained executive leadership experience by serving as Vice President of Finance for a publicly held medical device company in Minneapolis.

Mr. Zenk received a Master of Business Administration degree in Finance from the Carlson School of Management at the University of Minnesota in 1982.  Before attending Carlson, he graduated from St. John’s University in Collegeville, MN with a Bachelor of Science degree in Business Administration.